[P02BB01, trichlorfon, The metabolism of Succinylcholine can be decreased when combined with Metrifonate.]
[S02DA03, antipyrine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Antipyrine.]
[J01GA01, streptomycin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Streptomycin.]
[J01EC01, sulfamethoxazole, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Sulfamethoxazole.]
[M01AB02, sulindac, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Sulindac.]
[N05AL01, sulpiride, The metabolism of Succinylcholine can be decreased when combined with Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Sulthiame.]
[M01AX04, apazone, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Azapropazone.]
[N06DA01, tacrine, The metabolism of Succinylcholine can be decreased when combined with Tacrine.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Temazepam.]
[L01CB02, teniposide, Succinylcholine may increase the neurotoxic activities of Teniposide.]
[R03CC03, terbutaline, The serum concentration of Succinylcholine can be increased when it is combined with Terbutaline.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tetracaine.]
[S03AA02, tetracycline, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Tetracycline.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Apomorphine.]
[L04AX02, thalidomide, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Thiethylperazine.]
[L01AC01, thiotepa, The metabolism of Succinylcholine can be decreased when combined with Thiotepa.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Thiopental.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Thiothixene.]
[B02AB01, aprotinin, The metabolism of Succinylcholine can be decreased when combined with Aprotinin.]
[G04BE06, moxisylyte, The serum concentration of Moxisylyte can be increased when it is combined with Succinylcholine.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tiapride.]
[N02AX01, tilidine, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Tilidine.]
[S01ED01, timolol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Timolol.]
[P01AB02, tinidazole, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Tinidazole.]
[S01AA12, tobramycin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Tobramycin.]
[M02AA21, tolmetin, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tolmetin.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of CNS depression can be increased when Succinylcholine is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Trazodone.]
[S01BA05, triamcinolone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Triamcinolone.]
[C03DB02, triamterene, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Triamterene.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Triazolam.]
[A03AB12, mepenzolate, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[S01EB04, demecarium, The metabolism of Succinylcholine can be decreased when combined with Demecarium.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Trifluoperazine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Trifluperidol.]
[N05AA05, triflupromazine, The metabolism of Succinylcholine can be decreased when combined with Triflupromazine.]
[D07AC02, fluclorolone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluclorolone.]
[N04AA01, trihexyphenidyl, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[R03BA07, mometasone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Mometasone.]
[A03AA05, trimebutine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Trimethadione.]
[C02BA01, trimethaphan, The serum concentration of Trimethaphan can be increased when it is combined with Succinylcholine.]
[J01EA01, trimethoprim, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Trimethoprim.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Trimipramine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Triprolidine.]
[A03BB01, butylscopolamine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Succinylcholine.]
[C09CA09, azilsartan medoxomil, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Azilsartan medoxomil.]
[M03AA02, tubocurarine, The metabolism of Succinylcholine can be decreased when combined with Tubocurarine.]
[S01AA05, tyrothricin, The metabolism of Succinylcholine can be decreased when combined with Tyrothricin.]
[S01AA28, vancomycin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Vancomycin.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ezogabine.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Viloxazine.]
[L01CA02, vincristine, Succinylcholine may increase the neurotoxic activities of Vincristine.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Zuclopenthixol.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Levetiracetam.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ziprasidone.]
[G03AC10, drospirenone, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Drospirenone.]
[N02BA01, aspirin, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Acetylsalicylic acid.]
[G04BD07, tolterodine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Atenolol.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Atracurium.]
[S01FA01, atropine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[H02AB11, prednylidene, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Prednylidene.]
[M03BX01, baclofen, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Baclofen.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Mirabegron can be increased when it is combined with Succinylcholine.]
[A02AA05, magnesium silicate, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium silicate.]
[H02AA01, aldosterone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Aldosterone.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Barbital.]
[C01AA01, acetyldigitoxin, The risk or severity of Cardiac Arrhythmia can be increased when Succinylcholine is combined with Acetyldigitoxin.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Rasagiline.]
[C08CA13, lercanidipine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mosapride.]
[N06DA02, donepezil, The metabolism of Succinylcholine can be decreased when combined with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Zolmitriptan.]
[R06AC06, thonzylamine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Diethyl ether.]
[C04AX11, bencyclane, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Bencyclane.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pomalidomide.]
[N02BA10, benorilate, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Benperidol.]
[A10BK02, canagliflozin, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Canagliflozin.]
[A12CC09, magnesium orotate, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium orotate.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Benzocaine.]
[M01AH01, celecoxib, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Naratriptan.]
[A12CC05, magnesium aspartate, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium aspartate.]
[N04AC01, benztropine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[R02AX03, benzydamine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Levomilnacipran.]
[C08EA02, bepridil, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Bepridil.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Vortioxetine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Eslicarbazepine.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Vigabatrin.]
[C07AB04, acebutolol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Acebutolol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tasimelteon.]
[A16AA06, betaine, The metabolism of Succinylcholine can be decreased when combined with Betaine.]
[S03BA03, betamethasone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Betamethasone.]
[S01ED02, betaxolol, The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Succinylcholine.]
[A03BA03, hyoscyamine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Alfaxalone.]
[D11AA01, glycopyrronium, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[S01AA15, dihydrostreptomycin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Dihydrostreptomycin.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Acepromazine.]
[A06AH03, naloxegol, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Naloxegol.]
[N04AA02, biperiden, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[S03AA06, gentamicin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Gentamicin.]
[N06AX11, mirtazapine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[A03AA09, difemerine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[A07DA06, eluxadoline, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Acetazolamide.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Acetophenazine.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Brivaracetam.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium Aluminum Silicate.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dexbrompheniramine.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Amineptine.]
[C08CA01, amlodipine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Amlodipine.]
[N05AX17, pimavanserin, Succinylcholine may increase the neurotoxic activities of Pimavanserin.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Aniracetam.]
[C03CA02, bumetanide, Bumetanide may decrease the neuromuscular blocking activities of Succinylcholine.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Bupranolol.]
[N07BC01, buprenorphine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Buspirone.]
[N06DA03, rivastigmine, The metabolism of Succinylcholine can be decreased when combined with Rivastigmine.]
[N02AF01, butorphanol, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Butorphanol.]
[S01GX07, azelastine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[A07EC04, balsalazide, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Balsalazide.]
[R03CC12, bambuterol, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Bambuterol.]
[N02BF02, pregabalin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Beclamide.]
[C09AA07, benazepril, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Benazepril.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Oxybuprocaine.]
[R05DB01, benzonatate, The serum concentration of Benzonatate can be increased when it is combined with Succinylcholine.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Safinamide.]
[A02BX12, bismuth subnitrate, Succinylcholine may increase the neurotoxic activities of Bismuth subnitrate.]
[C07AB07, bisoprolol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Bisoprolol.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Efavirenz.]
[C07AA17, bopindolol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Bopindolol.]
[N04AA11, bornaprine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Brotizolam.]
[C03DA03, canrenone, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Canrenone.]
[R03BA02, budesonide, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Budesonide.]
[M01AB07, bumadizone, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Butobarbital.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Butriptyline.]
[C01AA02, acetyldigoxins, Succinylcholine may increase the arrhythmogenic activities of Acetyldigoxin.]
[N01BX04, capsaicin, The metabolism of Succinylcholine can be decreased when combined with Capsaicin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Vinylbital.]
[C09AA01, captopril, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Captopril.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Carbamazepine.]
[A03AA03, camylofine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Carbinoxamine.]
[C07AG02, carvedilol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Carvedilol.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Succinylcholine.]
[J01GB14, plazomicin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Plazomicin.]
[C07AB08, celiprolol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Celiprolol.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Stiripentol.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cetirizine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Lornoxicam.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Succinylcholine.]
[R03BB08, revefenacin, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[C09AA08, cilazapril, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Cilazapril.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cinitapride.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Esketamine.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clobazam.]
[J01AA11, clomocycline, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Clomocycline.]
[H02AB14, cloprednol, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Cloprednol.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cloxazolam.]
[C09CA06, candesartan, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Candesartan.]
[H02AB17, cortivazol, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Cortivazol.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cyamemazine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Succinylcholine.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Yohimbine.]
[H02AB13, deflazacort, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Deflazacort.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Succinylcholine.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dexbrompheniramine.]
[N02AX03, dezocine, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lumateperone.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Frovatriptan.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dichloralphenazone.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Eletriptan.]
[M01AH02, rofecoxib, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Rofecoxib.]
[C08CA16, clevidipine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Clevidipine.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Valpromide.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Chlordiazepoxide.]
[A03AA08, dihexyverine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[D07XB03, fluprednidene, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluprednidene.]
[G04BD09, trospium, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Droxicam.]
[M02AA27, dexketoprofen, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dyclonine.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Succinylcholine is combined with Remimazolam.]
[N07XX04, sodium oxybate, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Sodium oxybate.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Succinylcholine is combined with Oliceridine.]
[P01BA01, chloroquine, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Chloroquine.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Succinylcholine can be decreased when combined with Chlorpromazine.]
[N05AF03, chlorprothixene, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Chlorzoxazone.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Etifoxine.]
[N02BA07, ethenzamide, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Ethenzamide.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ethyl loflazepate.]
[M01AB08, etodolac, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Etofenamate.]
[L01FX21, naxitamab, Succinylcholine may increase the neurotoxic activities of Naxitamab.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Fenbufen.]
[R03BA03, flunisolide, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluocinolone acetonide.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Trichloroethylene.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Gabapentin.]
[N07CA02, cinnarizine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Cinnarizine.]
[L01XA01, cisplatin, The metabolism of Succinylcholine can be decreased when combined with Cisplatin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Citalopram.]
[C03DA05, finerenone, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Finerenone.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clemastine.]
[M01AG01, mefenamic acid, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Mefenamic acid.]
[J01FF01, clindamycin, The risk or severity of neuromuscular blockade can be increased when Clindamycin is combined with Succinylcholine.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Succinylcholine is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Succinylcholine.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Levobupivacaine.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Succinylcholine.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Granisetron.]
[N05AH02, clozapine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[J01GB12, arbekacin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Arbekacin.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Halazepam.]
[S02DA02, cocaine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Succinylcholine may increase the sedative activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Codeine.]
[M03AC05, hexafluorenium, The metabolism of Succinylcholine can be decreased when combined with Hexafluronium.]
[A03AB10, hexocyclium, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[J01XB01, colistin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Colistin.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ifenprodil.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Imidazole salicylate.]
[R03BA08, ciclesonide, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Desloratadine.]
[M01AH03, valdecoxib, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Valdecoxib.]
[H01AX01, pegvisomant, The metabolism of Succinylcholine can be decreased when combined with Pegvisomant.]
[C01AA06, lanatoside C, The risk or severity of Cardiac Arrhythmia can be increased when Succinylcholine is combined with Lanatoside C.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Almotriptan.]
[M01AH04, parecoxib, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Parecoxib.]
[J02AC02, itraconazole, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Bemiparin.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ketazolam.]
[M01AA06, kebuzone, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Kebuzone.]
[C08CA09, lacidipine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Lacidipine.]
[N03AX09, lamotrigine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[S01BA03, cortisone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Cortisone.]
[N07BC04, lofexidine, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lormetazepam.]
[M02AA31, loxoprofen, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Loxoprofen.]
[C09AA03, lisinopril, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Lisinopril.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium carbonate.]
[B05XA10, magnesium phosphate, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium phosphate.]
[C08CA11, manidipine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Manidipine.]
[A03AA04, mebeverine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Medifoxamine.]
[C07AA14, mepindolol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Mepindolol.]
[H02AB15, meprednisone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Meprednisone.]
[N04AA03, methixene, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[C04AX01, cyclandelate, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Cyclandelate.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cyclobarbital.]
[C03DA04, eplerenone, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Eplerenone.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Melperone.]
[L01AA01, cyclophosphamide, The serum concentration of Succinylcholine can be increased when it is combined with Cyclophosphamide.]
[N06AX07, minaprine, The metabolism of Succinylcholine can be decreased when combined with Minaprine.]
[J04AB01, cycloserine, Succinylcholine may increase the neurotoxic activities of Cycloserine.]
[S01XA18, cyclosporine, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Moclobemide.]
[R06AX02, cyproheptadine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Moexipril.]
[M02AA02, mofebutazone, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Morniflumate.]
[M01AH05, etoricoxib, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Etoricoxib.]
[M03CA01, dantrolene, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Dantrolene.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.]
[M01AX01, nabumetone, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nabumetone.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Succinylcholine.]
[J01AA01, demeclocycline, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Demeclocycline.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Nordazepam.]
[C07AB12, nebivolol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nebivolol.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Niaprazine.]
[C01DX16, nicorandil, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nicorandil.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tiagabine.]
[M03AC11, cisatracurium, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Succinylcholine.]
[R05DA06, normethadone, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Escitalopram.]
[G04BD08, solifenacin, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Olsalazine.]
[N06AA01, desipramine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[C01AA07, deslanoside, The risk or severity of Cardiac Arrhythmia can be increased when Succinylcholine is combined with Deslanoside.]
[D07XC02, desoximetasone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Desoximetasone.]
[H02AA03, desoxycorticosterone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Desoxycortone.]
[C09XA02, aliskiren, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Oxiracetam.]
[N04AA08, dexetimide, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dextromethorphan.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Paramethadione.]
[N02AC01, dextromoramide, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Paroxetine.]
[N07BC06, heroin, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Diamorphine.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Phenacemide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Phensuximide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dibenzepin.]
[S02DA04, dibucaine, The metabolism of Succinylcholine can be decreased when combined with Cinchocaine.]
[S01BC03, diclofenac, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Diclofenac.]
[A03AA07, dicyclomine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Succinylcholine may increase the neurotoxic activities of Didanosine.]
[A03AX04, pinaverium, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Pinaverium.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pipamperone.]
[A03AB14, pipenzolate, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[C03CA03, piretanide, Piretanide may decrease the neuromuscular blocking activities of Succinylcholine.]
[P02CB02, diethylcarbamazine, The metabolism of Succinylcholine can be decreased when combined with Diethylcarbamazine.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Diethylpropion.]
[C08CA03, isradipine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Isradipine.]
[D07XC04, diflucortolone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Difluocortolone.]
[A03AB11, poldine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Diflunisal.]
[C01AA04, digitoxin, The risk or severity of Cardiac Arrhythmia can be increased when Succinylcholine is combined with Digitoxin.]
[C01AA05, digoxin, Succinylcholine may increase the arrhythmogenic activities of Digoxin.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dihydroergotamine.]
[N02AA03, hydromorphone, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Hydromorphone.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Succinylcholine.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dimenhydrinate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pridinol.]
[R06AB03, dimethindene, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Progabide.]
[N02BB04, propyphenazone, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Proglumetacin.]
[R06AA02, diphenhydramine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Quazepam.]
[C09AA06, quinapril, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Quinapril.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of hyperkalemia can be increased when Ramipril is combined with Succinylcholine.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Remoxipride.]
[C01BA03, disopyramide, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N07AA03, distigmine, The metabolism of Succinylcholine can be decreased when combined with Distigmine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Riluzole.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ropivacaine.]
[C03XA01, tolvaptan, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tolvaptan.]
[S01BC05, ketorolac, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Ketorolac.]
[N02BA06, salsalate, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Salsalate.]
[N06AA16, dothiepin, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[N06AA12, doxepin, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[J01AA02, doxycycline, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Doxycycline.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of hyperkalemia can be increased when Sevoflurane is combined with Succinylcholine.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Sibutramine.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Succinylcholine.]
[C09AA11, spirapril, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Spirapril.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Sumatriptan.]
[V04CX07, edrophonium, The metabolism of Succinylcholine can be decreased when combined with Edrophonium.]
[C07AB13, talinolol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Talinolol.]
[H01AA01, corticotropin, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Corticotropin.]
[M01AC02, tenoxicam, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tenoxicam.]
[G04BD05, terodiline, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Terodiline.]
[C07AA16, tertatolol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tertatolol.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Thiopropazate.]
[G04BD01, emepronium, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Toloxatone.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Topiramate.]
[C03CA04, torsemide, Torasemide may decrease the neuromuscular blocking activities of Succinylcholine.]
[J01AA12, tigecycline, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Tigecycline.]
[C09AA10, trandolapril, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Trandolapril.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Triclofos.]
[A03AB08, tridihexethyl, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[H02CA01, trilostane, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Trilostane.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Trimethobenzamide.]
[N04AA12, tropatepine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Enflurane.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Veralipride.]
[L01CA04, vinorelbine, Succinylcholine may increase the neurotoxic activities of Vinorelbine.]
[S01FB02, ephedrine, The serum concentration of Ephedrine can be increased when it is combined with Succinylcholine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Epinastine.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Venlafaxine.]
[C08CA12, mepirodipine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Barnidipine.]
[C09AA15, zofenopril, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Zofenopril.]
[N05CF02, zolpidem, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Zonisamide.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Moricizine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ergotamine.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Valproic acid.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Estazolam.]
[R03BA09, fluticasone furoate, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluticasone.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Succinylcholine.]
[N04AA05, profenamine, The metabolism of Succinylcholine can be decreased when combined with Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ethosuximide.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ethotoin.]
[M01AC06, meloxicam, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Ethylmorphine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Etomidate.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Sertindole.]
[L04AD02, tacrolimus, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tacrolimus.]
[A02BA04, nizatidine, The metabolism of Succinylcholine can be decreased when combined with Nizatidine.]
[R06AX12, terfenadine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Fluvoxamine.]
[C08CA02, felodipine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Fendiline.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Fenoprofen.]
[N02AB03, fentanyl, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Fentanyl.]
[G04BD02, flavoxate, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[N02BG04, floctafenine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Floctafenine.]
[J02AC01, fluconazole, The risk or severity of hyperkalemia can be increased when Fluconazole is combined with Succinylcholine.]
[H02AA02, fludrocortisone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fludrocortisone.]
[D07XB01, flumethasone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Flumethasone.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Flunitrazepam.]
[D07AC08, fluocinonide, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluocinonide.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Melitracen.]
[H02AB03, fluocortolone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluocortolone.]
[V03AZ01, ethanol, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[S01CB05, fluorometholone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluorometholone.]
[N06AB03, fluoxetine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Flurazepam.]
[S01BC04, flurbiprofen, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Fluspirilene.]
[S01AA07, framycetin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Framycetin.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Furazolidone.]
[C03CA01, furosemide, Furosemide may increase the skeletal muscle relaxing activities of Succinylcholine.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Succinylcholine is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Amisulpride.]
[N06DA04, galantamine, The metabolism of Succinylcholine can be decreased when combined with Galantamine.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Gallamine.]
[C08DA02, gallopamil, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Gallopamil.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Bifemelane.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cabergoline.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Alfentanil.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Glutethimide.]
[C07AB09, esmolol, The risk or severity of hyperkalemia can be increased when Esmolol is combined with Succinylcholine.]
[C09AA09, fosinopril, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Fosinopril.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Succinylcholine.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Halothane.]
[N05AH04, quetiapine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Iprazochrome.]
[L01CE02, irinotecan, The serum concentration of Irinotecan can be increased when it is combined with Succinylcholine.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Allobarbital.]
[C09CA01, losartan, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Losartan.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Heparin.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium citrate.]
[A12CC03, magnesium gluconate, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium gluconate.]
[A07EC02, mesalamine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Mesalazine.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Hexobarbital.]
[C08CA10, nilvadipine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nimesulide.]
[C09AA04, perindopril, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Perindopril.]
[R05DA03, hydrocodone, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Hydrocortisone.]
[D07AB02, hydrocortisone butyrate, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Hydrocortisone butyrate.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Succinylcholine.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Succinylcholine.]
[A12BA02, potassium citrate, Potassium citrate may increase the hyperkalemic activities of Succinylcholine.]
[G04BD06, propiverine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.]
[R02AX02, ibuprofen, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Ibuprofen.]
[B05CB02, sodium citrate, Succinylcholine may increase the neurotoxic activities of Sodium citrate.]
[N01AH03, sufentanil, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Sufentanil.]
[N06AA02, imipramine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.]
[L01CD01, paclitaxel, Succinylcholine may increase the neurotoxic activities of Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Tixocortol.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tizanidine.]
[S01BC01, indomethacin, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Indomethacin.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Milnacipran.]
[A03AA30, piperidolate, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Articaine.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Alprazolam.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ramelteon.]
[R06AE01, buclizine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Alprenolol.]
[J05AF04, stavudine, Succinylcholine may increase the neurotoxic activities of Stavudine.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Isocarboxazid.]
[C09AA16, imidapril, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Isoflurane.]
[S01EB07, isoflurophate, The metabolism of Succinylcholine can be decreased when combined with Isoflurophate.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Entacapone.]
[R03CB01, isoproterenol, The metabolism of Succinylcholine can be decreased when combined with Isoprenaline.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Reboxetine.]
[S01AA24, kanamycin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Kanamycin.]
[N01AX03, ketamine, The metabolism of Succinylcholine can be decreased when combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ketanserin.]
[J02AB02, ketoconazole, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Ketoconazole.]
[N05AH03, olanzapine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Ketoprofen.]
[N04BC09, rotigotine, Succinylcholine may increase the sedative activities of Rotigotine.]
[M01AE11, tiaprofenic acid, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Labetalol.]
[N07AA30, ambenonium, The metabolism of Succinylcholine can be decreased when combined with Ambenonium.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lacosamide.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Etacrynic acid.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Lidoflazine.]
[J01FF02, lincomycin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Lincomycin.]
[C03DB01, amiloride, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Amiloride.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lisuride.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lofepramine.]
[A07DA03, loperamide, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Loperamide.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Succinylcholine.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Loxapine.]
[J01AA04, lymecycline, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Lymecycline.]
[B05XA11, magnesium chloride, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium chloride.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium oxide.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium sulfate.]
[V04CX04, mannitol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Mannitol.]
[N06AA21, maprotiline, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mazindol.]
[C02BB01, mecamylamine, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Mecamylamine.]
[L01AA05, mechlorethamine, The metabolism of Succinylcholine can be decreased when combined with Mechlorethamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Meclizine.]
[M02AA18, meclofenamic acid, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Medazepam.]
[C01AA08, medigoxin, Succinylcholine may increase the arrhythmogenic activities of Metildigoxin.]
[P01BC02, mefloquine, The metabolism of Succinylcholine can be decreased when combined with Mefloquine.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Dalteparin.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Melatonin.]
[N06DX01, memantine, The metabolism of Succinylcholine can be decreased when combined with Memantine.]
[N02AB02, meperidine, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Meperidine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mephenytoin.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Meprobamate.]
[N02AX05, meptazinol, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dolasetron.]
[J01AA05, methacycline, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Metacycline.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Succinylcholine.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Metamfetamine.]
[A03AB07, methantheline, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Metharbital.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Metergoline.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methocarbamol.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methohexital.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methoxyflurane.]
[V04CG05, methylene blue, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methylene blue.]
[H02AB04, methylprednisolone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Methylprednisolone.]
[D07AC14, methylprednisolone aceponate, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Methylprednisolone aceponate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Succinylcholine.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methysergide.]
[A03FA01, metoclopramide, The metabolism of Succinylcholine can be decreased when combined with Metoclopramide.]
[C07AB02, metoprolol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Metoprolol.]
[P01AB01, metronidazole, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Metronidazole.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mianserin.]
[S02AA13, miconazole, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Aminophenazone.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Parnaparin.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Midazolam.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tinzaparin.]
[C09CA03, valsartan, The risk or severity of hyperkalemia can be increased when Valsartan is combined with Succinylcholine.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Molindone.]
[C01BD01, amiodarone, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Amiodarone.]
[N06AA09, amitriptyline, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Morphine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Palonosetron.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Ammonium chloride.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Amobarbital.]
[R03BB01, ipratropium bromide, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The therapeutic efficacy of Succinylcholine can be decreased when used in combination with Fosphenytoin.]
[C07AA12, nadolol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nadolol.]
[N04BC04, ropinirole, Succinylcholine may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Nalbuphine.]
[N07BB04, naltrexone, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Naltrexone.]
[M02AA12, naproxen, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Naproxen.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tolcapone.]
[S03AA01, neomycin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Neomycin.]
[N01AH06, remifentanil, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Remifentanil.]
[S01EB06, neostigmine, The metabolism of Succinylcholine can be decreased when combined with Neostigmine.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Iloperidone.]
[S01AA23, netilmicin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Netilmicin.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Desvenlafaxine.]
[C09CA07, telmisartan, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Telmisartan.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Nialamide.]
[C08CA04, nicardipine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[C08CA05, nifedipine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Niflumic acid.]
[C08CA06, nimodipine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nimodipine.]
[C08CA07, nisoldipine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Nitrazepam.]
[C08CA08, nitrendipine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nitrendipine.]
[J01XE01, nitrofurantoin, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nitrofurantoin.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Zaleplon.]
[N04BC05, pramipexole, Succinylcholine may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Nomifensine.]
[N06AA10, nortriptyline, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.]
[G02CA02, nylidrin, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nylidrin.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Reviparin.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Opipramol.]
[N02AA02, opium, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Opium.]
[P01AB03, ornidazole, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Ornidazole.]
[C01AC01, ouabain, The risk or severity of Cardiac Arrhythmia can be increased when Succinylcholine is combined with Ouabain.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Oxazepam.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Oxycodone.]
[N02AA11, oxymorphone, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[S01AA04, oxytetracycline, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Oxytetracycline.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Asenapine.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Danaparoid.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.]
[M03AC01, pancuronium, The metabolism of Succinylcholine can be decreased when combined with Pancuronium.]
[J04AB30, capreomycin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Capreomycin.]
[N05CC05, paraldehyde, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[H02AB05, paramethasone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Paramethasone.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pargyline.]
[A07AA06, paromomycin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Paromomycin.]
[G04BD11, fesoterodine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pentobarbital.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pergolide.]
[C08EX02, perhexiline, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Perhexiline.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Perphenazine.]
[N02AD02, phenazocine, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Phenazocine.]
[N06AF03, phenelzine, Phenelzine may increase the neuromuscular blocking activities of Succinylcholine.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Phenoperidine.]
[M02AA01, phenylbutazone, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Phenylbutazone.]
[N03AB02, phenytoin, The therapeutic efficacy of Succinylcholine can be decreased when used in combination with Phenytoin.]
[V03AB19, physostigmine, The metabolism of Succinylcholine can be decreased when combined with Physostigmine.]
[C08CX01, mibefradil, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pindolol.]
[J01CA12, piperacillin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Piperacillin.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pipotiazine.]
[C09CA02, eprosartan, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Eprosartan.]
[A02BX03, pirenzepine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Piritramide.]
[S01BC06, piroxicam, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Piroxicam.]
[N02CX01, pizotyline, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[C09CA04, irbesartan, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Proxibarbal.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Alosetron.]
[S03AA03, polymyxin B, Succinylcholine may increase the neurotoxic activities of Polymyxin B.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Succinylcholine.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Succinylcholine.]
[C07AB01, practolol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Practolol.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Prazepam.]
[S03BA02, prednisolone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Prednisone.]
[C01DX02, prenylamine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Prilocaine.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Primidone.]
[C01BA02, procainamide, The metabolism of Succinylcholine can be decreased when combined with Procainamide.]
[S01HA05, procaine, The metabolism of Succinylcholine can be decreased when combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Procarbazine.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Prochlorperazine.]
[N04AA04, procyclidine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[N05AA03, promazine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Propanidid.]
[A03AB05, propantheline, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Periciazine.]
[N05CM06, propiomazine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Propofol.]
[N02AC04, propoxyphene, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Propranolol.]
[C01AB01, proscillaridin, The risk or severity of Cardiac Arrhythmia can be increased when Succinylcholine is combined with Proscillaridin.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Rizatriptan.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Protriptyline.]
[N05AX12, aripiprazole, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Talbutal.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pyrantel.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Succinylcholine.]
[N07AA02, pyridostigmine, The metabolism of Succinylcholine can be decreased when combined with Pyridostigmine.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mepyramine.]
[C01BA01, quinidine, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Quinidine.]
[P01BC01, quinine, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Quinine.]
[C02AA01, rescinnamine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Reserpine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Oxitriptan.]
[J01AA09, rolitetracycline, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Rolitetracycline.]
[N02BA05, salicylamide, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Salicylic acid.]
[S01FA02, scopolamine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Secobarbital.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Selegiline.]
[J01GB08, sisomicin, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Sisomicin.]
[C07AA07, sotalol, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Sotalol.]
[C03DA01, spironolactone, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Spironolactone.]
